Objective: A large body of evidence has shown the possible relevance of polymorphisms of the genes that encode glutathione S-transferase m, p and u (GSTM1, GSTP1 and GST1, respectively) to the susceptibility of acute myeloid leukemia, but the exact association still remains uncertain. Therefore, we performed a meta-analysis to derive a more precise estimation of the relationship. Methods: A comprehensive literature search of PubMed and Web of Knowledge electronic databases was conducted to collect relevant studies until 20 February 2014. References of the retrieved articles were also screened. The extracted data were statistically analyzed, and pooled odds ratios with 95% confidence intervals were calculated to estimate the association strength using Review Manager version 5.2. Results: Twenty-nine studies were included in the meta-analysis. The pooled analyses revealed that the GSTM1-null genotype was associated with an increased risk of acute myeloid leukemia in East Asians (P ¼ 0.01; odds ratio ¼ 1.22; 95% confidence interval ¼ 1.05 -1.42), and GSTT1-null genotype in Caucasians (P , 0.0001; odds ratio ¼ 1.48; 95% confidence interval ¼ 1.29 -1.69). There was also a predilection towards the female gender for both of these polymorphisms. For GSTP1 Ile105Val polymorphism, no significant association was found under any contrast model. In addition, the presence of the double-null genotypes increased the risk of acute myeloid leukemia in both Caucasians and East Asians. Conclusions: This meta-analysis suggested that heritable GST status could influence the risk of developing acute myeloid leukemia.
INTRODUCTION
Acute myeloid leukemia (AML) is a clonal disorder that is characterized by the abnormal accumulation of white blood cells in the bone marrow and which interferes with the normal production of blood cells (1) . The etiology of AML was found to be multifactorial; however, exposure to carcinogens such as benzene and ionizing radiation is thought to result in DNA damage at the level of hematopoietic progenitor cells, which is an essential prerequisite for the development of AML (2) .
DNA is at constant risk of being damaged by both endogenous and exogenous mechanisms. Cells have highly effective pathways for repairing DNA damage and maintaining their genomic integrity. The inability to respond adequately to DNA damage or failure to accurately repair DNA damage could lead to genetic instability, which may in turn increase the susceptibility to cancer (3, 4) . Thus, exposure to toxic substances could cause DNA damage, which when combined with interindividual differences in the capacity to respond to and repair that DNA damage could affect the susceptibility to AML.
The genetic polymorphisms that have been described for multiple genes associated with DNA repair may contribute to the reported variation in the ability to detoxify (5) , which could explain the mechanism of individual differences in susceptibility to AML. The glutathione S-transferases (GSTs) are a family of Phase II enzymes that are involved in the detoxification of xenobiotics. They catalyze the conjugation reaction between glutathione and compounds containing an electrophilic center, such as chemotherapeutic drugs, carcinogens, environmental pollutants and a broad spectrum of other xenobiotics (6) . Hence, GSTs play a significant role in cellular defense. Human cytosolic GSTs can be characterized into four distinct families according to their isoelectric points: a, m, p and u (7).
Functional polymorphisms have been reported for at least three of the genes that encode GSTs: GSTM1 (m), GSTT1 (u) and GSTP1 (p). Both GSTM1 and GSTT1 exhibit a particularly high degree of polymorphism, and one of them being the complete deletion of the gene could potentially cause a loss of enzymatic activity (8) . Approximately 20 -50% of individuals do not express the enzyme due to homozygous deletion, resulting in a diminished ability to detoxify various carcinogens; these individuals are more susceptible to DNA damage (9) . GSTP1 is located on chromosome 11q13 and is overexpressed in various tumor types (10) . The A ! G polymorphism at nucleotide 313 in exon 5 of GSTP1 can lead to an amino acid substitution of isoleucine (Ile) by valine (Val) at amino acid position 105 (Ile105Val). This substitution potentially diminishes the ability to detoxify certain mutagens and carcinogens. (11) . Biochemical studies have indicated that the conjugating activity is lower for Val homozygotes than for Ile homozygotes, with heterozygotes displaying intermediate activity (12) . In brief, these three polymorphisms mentioned above could affect the ability of the GSTs to detoxify certain mutagens and carcinogens, which could result in a greater risk of developing AML.
Numerous studies had investigated the association between these polymorphisms and the susceptibility to AML. However, the findings of these studies are conflicting. The possible reasons for these discrepancies include differences in ethnicity, sample sizes and the age of the patients between the studies. The aim of the present meta-analysis study was to determine the role of GSTM1, GSTT1 and GSTP1 polymorphisms in the risk of AML.
PATIENTS AND METHODS

SEARCH STRATEGY
All relevant studies published before 20 February 2014 were identified through an extended computer-based search of PubMed (www.ncbi.nlm.nih.gov/pubmed, 11 August 2014, date last accessed) and Web of Knowledge (http://isiknowledge. com/, 11 August 2014, date last accessed). The search strategy was based on a combination of the following keywords: 'GSTM1', 'GSTT1', 'GSTP1', 'acute myeloid leukemia' ('AML' or 'acute myelocytic leukemia' or 'acute myelogenous leukemia'), 'chronic myeloid leukemia' ('CML' or 'chronic myelocytic leukemia' or 'chronic myelogenous leukemia'), 'polymorphism', 'susceptibility' and 'risk'. Only journal articles were included in the analysis. All references cited in the studies were also reviewed to identify additional relevant work. Only studies involving human subjects using standard genotyping methods were considered. Cases with AML were eligible regardless of whether or not they had a first-degree relative with any cancer.
INCLUSION CRITERIA
The following inclusion criteria were applied:
(i) The study must have a case -control design and investigate the relationship between GSTM1, GSTT1 and GSTP1 polymorphisms and the risk of AML. (ii) The study must provide sufficient data on the distribution of GST gene polymorphisms in cases and in control groups of healthy subjects, or sufficient information for such data to be calculated. (iii) The cases considered in the study must include a population of AML patients.
DATA EXTRACTION
The following information was extracted for the included studies: name of the first author, year of publication, numbers of patients and controls, ethnicities of the study population, median ages of the cases and controls, sex ratios of the cases and controls, genotype distributions for the cases and controls and main single-nucleotide polymorphism (SNP) susceptibility findings of the research.
GENETIC MODEL
For GSTM1 and GSTT1 polymorphisms, null (homozygous mutant) versus present (wild type or heterozygous) was assumed, consistent with all of the included studies. For GSTP1 Ile105Val, its role was assessed under the allele contrast (G versus A), the homozygotes contrast (GG versus AA), the dominant model (AG þ GG versus AA) and the recessive model (GG versus AG þ AA). The study would been excluded if the distribution of GSTP1 Ile105Val genotypes in controls deviated from Hardy -Weinberg equilibrium (HWE).
STATISTICAL ANALYSIS
Review Manager (version 5.2) software was used for the meta-analysis. The raw data for genotype distribution were used to calculate the study-specific estimates of odds ratio (OR) and 95% confidence interval (CI). The presence of heterogeneity was assessed using Cochran's Q-statistic (with a significance cutoff of P , 0.05) and quantified using the I an I 2 value .50% indicates the presence of a very high degree of heterogeneity (13) .
The overall pooled OR and corresponding 95% CI were estimated using the Mantel -Haenszel method with a fixed-effects model when no significant clinical or statistical heterogeneity is present (,50%) (14) . When substantial heterogeneity was present, subgroup analysis according to ethnicity was conducted. If heterogeneity in some subgroups was still high, sensitivity analysis was performed by excluding individual studies. Outlying studies were identified and excluded, and the I 2 estimates for these different sets of studies were examined. When removing particular studies did not cause the heterogeneity index to fall .50%, or the amount of included studies was relatively small, the random-effects model was used. This model can account for the heterogeneity in the data that undoubtedly exists due to within-and betweenstudy variations, and thus its estimated effect values are more conservative (13) . The significance of the polled OR was determined by a z-test. The level of statistical significance was set at P , 0.05.
Potential publication bias was estimated by constructing funnel plots. If most of the data appeared at the top of a funnel plot and was distributed roughly symmetrically, this would suggest the absence of obvious publication bias and vice versa (15) . There was no need to construct funnel plots when there were too few analyzed studies (i.e. n , 5).
RESULTS
OVERVIEW OF THE STUDY CHARACTERISTICS
A flow chart depicting the study selection process is shown in Fig. 1 . In total, 736 articles were selected based on various combinations of the keywords listed in the 'Patients and Methods' section. Checking for duplicates resulted in the removal of 352 articles. Of the remaining 384 articles, 81 did not focus on susceptibility to myeloid leukemia, 228 did not report the GST gene SNPs, 16 focused on researching the association between GST gene SNPs and the risk of CML, 26 were review articles and 4 did not provide sufficient data. After excluding these articles, only 29 studies qualified for inclusion in this meta-analysis. The basic data for every eligible study were extracted and are listed in Table 1 . These studies were conducted in various populations of different ethnicities: 13 involved Caucasians (16,18,19,22,24 -26,29,31,33,34, 39,40) , 8 involved East Asians (1,27,30,32,35 -38 ) and 8 involved mixed-race (2, 5, 11, 17, 20, 21, 23, 28) .
RESULTS OF THE META-ANALYSIS
Among the included studies, 25 investigated the distribution of GSTM1 polymorphisms in AML patients and controls (see Table 1 ) and provided sufficient data for analysis. Furthermore, 0 (null) GSTM1-null genotype in the control group was found in the study of Eyada et al. (24) . As the standard statistics cannot properly cope with it, we therefore excluded this study. A meta-analysis of the left 24 studies was performed on the data from 4852 patients and 8639 controls. The forest plot revealed a high degree of heterogeneity with the fixed-effects model, and therefore, subgroup analyses were conducted. After that, only in East Asians, GSTM1-null genotype was found to significantly increase the risk of AML (P ¼ 0.01; OR ¼ 1.22; 95% CI ¼ 1.05 -1.42). The funnel plot showed no obvious publication bias ( Fig. 2A) .
A meta-analysis was applied to the 22 studies of the effect of the GSTT1 polymorphism on the susceptibility to AML provided data from 4144 patients and 7710 controls. With the fixed-effects model, the forest plot revealed a high degree of heterogeneity among the 22 studies. After subgroup analyses according to ethnicity, we found that this SNP was significantly associated with increased risk of AML in Caucasians (P , 0.0001; OR ¼ 1.48; 95% CI ¼ 1.29 -1.69), while not in East Asians. No obvious publication bias was evident from the funnel plot (Fig. 2B) . 
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The data from 11 studies (1784 patients and 3405 controls) on the distribution of combined GSTM1-and GSTT1-null genotypes between AML cases and controls were subjected to a meta-analysis. The heterogeneity among these studies was very high and so we performed subgroup analyses. In the subgroup of Caucasians, the heterogeneity was still high and a sensitivity analysis was therefore undertaken, which identified the study by Gra et al. (25) as an outlier. Removal of the data of that study from the subgroup reduced the heterogeneity. Overall, in both Caucasians and East Asians, the combined double-null genotype could increase the risk of AML. The funnel plot did not reveal any obvious publication bias (Fig. 2C) .
Ten studies investigated the association between the GSTP1 Ile105Val polymorphism and the risk of AML. The distribution of the GSTP1 Ile105Val genotypes in controls was not in accordance with the HWE in five studies and hence, they were excluded (1, 11, 16, 31, 35) . A meta-analysis was conducted using the data of 852 cases and 2339 controls from additional five studies under the allele contrast (Fig. 3A) , the homozygotes contrast (Fig. 3B ), the dominant model (Fig. 3C ) and the recessive model (Fig. 3D ) (2, 20, 27, 34, 37) (the study of Yuan et al. was excluded in homozygotes contrast and recessive model as the number of GG genotype in the AML group was 0). No association between the SNP and the susceptibility to AML was found under any contrast model, and no heterogeneity was found under any model. Five studies researched the distribution of the GSTM1 polymorphism according to gender (22, 23, 25, 28, 38) . A metaanalysis of the data from five studies (involving 313 males and 228 females) revealed no difference in the distribution of GSTM1 polymorphism between male and female patients (Fig. 4A) . Four additional studies investigated the distribution of GSTT1 polymorphism according to gender (22,23,25,38) .
A meta-analysis of the data from these studies also showed no gender difference in this regard (Fig. 4B) .
The influence of the GSTM1-and GSTT1-null genotypes on the risk of AML was also analyzed according to gender. Three studies provided sufficient data for analyzing the distribution of the GSTM1 gene according to gender among both patients and controls (25, 28, 38) . A meta-analysis revealed that 
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GSTM1, T1 and P1 SNPs in the risk of AML compared with female controls, female AML patients had a greater frequency of the GSTM1-null genotype ( Fig. 5A ; P ¼ 0.03, OR ¼ 1.74, 95% CI ¼ 1.04 -2.88). No such difference was observed between male AML patients and male controls. In addition, only two studies provided sufficient data on the distribution of the GSTT1 gene according to gender among both patients and controls (25, 38) . A meta-analysis of those two studies demonstrated that the frequency of the GSTT1-null genotype was higher in the female patients than in the female controls ( Fig. 5B; noted that few studies were included in this analysis, and so further relevant research is needed to confirm the present data.
DISCUSSION
This study identified 29 articles describing research into the association between the GSTM1, GSTT1 and GSTP1 polymorphisms and the risk of AML. The conclusions among these studies were not consistent, which indicates an urgent need to develop a systematic method for drawing more precise conclusions. This situation prompted this study to use meta-analysis, a common method of systematic review, to integrate these contradictions and obtain more accurate results. All of the included articles were of high quality and presented a rigorous scientific design, accurate data and clear results. The influence of the three GST gene polymorphisms on the susceptibility to AML was analyzed using these data. The following main conclusions were drawn from the analyses: A meta-analysis similar to that presented herein was performed by Das et al. in 2009 , who investigated the influence of GSTM1, GSTT1 and GSTP1 Ile105Val polymorphisms on the susceptibility to AML (41) . However, the conclusions they drew were very different from ours. They found that only the GSTM1 polymorphism was a risk factor for AML, while the GSTT1 was not. Conversely, in this study it was found that the two SNPs were risk factors for AML in different ethnic populations. There are three main factors that could explain this discrepancy. First, in the work of Das et al., there were some discrepancies between the reported data and the actual data in the included studies. For example, Rollinson et al. (31) reported that the number of cases was 475, whereas Das et al. Majumdar et al. (28) , pooled the de novo and t-AML patients, rather than analyzing them separately. This indicates that the method of inputting data in that meta-analysis was inconsistent. In this study, data on both de novo and t-AML cases were merged to produce a more scientific model.
Third, the present meta-analyses included a greater number of studies than did the meta-analysis performed by Das et al. In particular, for the meta-analysis of the GSTP1 Ile105Val polymorphism, we included 10 articles while only three were included in the meta-analysis of Das et al. It is therefore possible that the present statistically significant findings are closer to the actual situation.
As is known to all, both Brazilian and Indian have mixed descent. Therefore, we classed them in the mixed-race group when conducting subgroup analyses. Heterogeneity in this group was obvious when the influence of each SNP on AML was analyzed, which was largely due to the intermixture of races. In addition, the study on this group could not explain the influence of SNPs on AML in some race, so this group was not the focus of this study.
The results of this study have important practical significance. The ability to detoxify intermediates varies between individuals, which in theory may explain differences in leukemia risk as a result of exogenous exposure (42) . Gene polymorphisms affect the activity of detoxification enzymes and thus cancer risk. Although there is a considerable amount of research on this topic, the results have not received sufficient attention in clinical settings. The present meta-analysis revealed that deletion of GSTM1 could increase the risk of susceptibility to AML in East Asians and deletion of GSTT1 in Caucasians. The discrepancy for the role of the two SNPs on different races might result from the fact that the genotype distribution of the two SNPs differs according to race. In any case, our study demonstrated genotype testing is very important, because it can identify people who are carrying the risk deletion genotypes that would make them more susceptible to AML induced by environmental carcinogens. If identified, these people will be able to take the necessary protective measures, which is particularly important for those with long-term exposure to environmental pollutants. In addition, although no association was found between GSTP1 Ile/Val SNP and the risk of AML, this meta-analysis was based on relatively small amount of cases and the statistical power was not strong. This conclusion, therefore, should be treated with caution. Furthermore, the GSTM1-and GSTT1-null genotypes appear to significantly affect the risk of AML particularly among females, and thus women carrying this genotype should be made aware of their more risk relative to men so that they too can avoid environmental carcinogens and radiation wherever possible though this conclusion was also based on not strong statistical power and reasons for that were not clear.
Three limitations of this meta-analysis should be considered when interpreting its findings. First, the number of studies included in some meta-analyses was low, as was the number of cases. It is recognized that the sample size plays an important role in predicting the association between genotypes and risk of cancer in case -control studies. Therefore, the inclusion of studies with very small samples may lead to an overestimation of the true association (41) . The results of meta-analyses that are based on relatively small numbers of studies should be interpreted with caution. Second, the results were based on unadjusted estimates; a more precise analysis should be conducted using data from individuals, which would allow researchers to adjust for covariates including age, ethnicity, family history, environmental factors and lifestyle. Third, only published studies were included in this meta-analysis. There is always a certain degree of publication bias, and non-significant or negative findings may be unpublished.
In conclusion, this meta-analysis suggests that the GSTM1-null genotype is a risk factor for AML in East Asians, and GSTT1-null genotype in Caucasians. In addition, the presence of the double-null genotypes could increase the risk of AML in both populations. Further large studies on this locus are recommended in order to confirm the findings of this study and to identify the underlying mechanisms.
